India IPO SEBI DRHP Activity Filings — April 02, 2026

Reallocating ₹500 Lakh to working capital (from ₹2110.13 Lakh to ₹2610.13 Lakh) enhances liquidity amid unutilized IPO proceeds, signaling prudent cash management

Introducing ₹250 Lakh for new Pharmaceutical business represents diversification into high-growth sector, shifting from retail SIS model

Allocating ₹600 Lakh for acquisitions from reallocated funds positions company for inorganic growth, potentially accretive post-IPO

High materiality (9/10) of postal ballot underscores strategic importance of reallocation to core operations

Board approval on March 30, 2026, for postal ballot demonstrates management conviction in revised objects despite original prospectus plans

Neutral sentiment with structured e-voting (April 2-May 1, 2026) provides transparency for investors

Sharp 78% cut in SIS capex (₹1733.26 Lakh to ₹383.26 Lakh) indicates original retail expansion model underperformed, raising execution concerns

₹3906.79 Lakh unutilized IPO proceeds (filed Jan 15, 2025) post-listing signals delays or inefficiencies in original capex deployment

Pivot to working capital and new ventures over capex may reflect weaker-than-expected free cash flow generation

No insider trading activity disclosed in filing, lacking positive conviction signals from management

Absence of forward guidance on pharma/acquisition timelines or targets limits visibility on new objects' impact

Requires >90% majority for postal ballot approval; failure could lock funds in underutilized SIS capex, e-voting closes May 1, 2026

₹3906.79 Lakh unutilized proceeds highlight poor deployment of original IPO objects, potential ongoing capex inefficiencies

78% SIS capex reduction (₹1350 Lakh cut) signals original Shop-in-Shop model failure, no period comparisons to quantify underperformance

New ₹250 Lakh pharma allocation lacks operational metrics or timelines, unproven venture post-IPO

₹600 Lakh for acquisitions without deal terms, valuations, or targets raises integration and overpayment concerns

Increased working capital needs (₹500 Lakh boost) may indicate cash burn or revenue pressures, no financial ratios provided

Absence of insider transactions/pledges provides no gauge on management conviction amid major reallocation

Results announced by May 3, 2026, post-cut-off March 20, 2026; stock volatility likely around e-voting period

>90% approval by May 3, 2026, unlocks ₹850 Lakh for pharma/acquisitions, driving diversification alpha

₹250 Lakh allocation to pharmaceuticals taps high-margin sector, potential re-rating if executed post-approval

₹600 Lakh for M&A from reallocated funds offers bolt-on growth, monitor for undervalued targets

₹500 Lakh working capital increase supports operations, positioning for near-term revenue acceleration

Successful variation demonstrates adaptability, attractive for investors seeking nimble post-listing plays

Transparent process (April 2-May 1, 2026) allows pre-results positioning on approval odds

₹1350 Lakh savings from SIS cut frees capital for higher-ROI uses, turnaround potential

High materiality (9/10) in low-volume period positions Earkart as standout for event-driven trades

Single filing shows shift from capex (78% SIS cut) to working capital (+24%) and new ventures (pharma/acq ₹850 Lakh), implying execution gaps in 1/1 tracked IPOs

>90% majority required for variations highlights governance hurdles in India IPO post-listing, neutral sentiment prevails

Introduction of pharma (₹250 Lakh) and acquisitions (₹600 Lakh) in retail/e-com IPO signals sector pivot to stability amid capex underutilization

₹3906.79 Lakh idle funds in sole filing points to common post-IPO deployment delays, no YoY/QoQ for broader trends

E-voting/results (May 1-3, 2026) as key event in quiet session, building IPO monitor calendar around approvals

Monitor >90% approval outcome by May 3, 2026, for reallocation impact on stock and strategy

Track participation from April 2- May 1, 2026 (cut-off March 20), gauge shareholder sentiment

Watch post-approval rollout of ₹250 Lakh allocation for timelines, partnerships, metrics

Follow ₹600 Lakh M&A developments for targets, valuations, deal terms post-May 2026

Monitor any transactions/pledges around e-voting period for management conviction signals

Await next filings for ratios, operational volumes on WC usage vs original SIS underperformance

Post-March 30, 2026 meeting, watch for further capex/diversification guidance